Peer-reviewed #oncology journal examining the molecular basis of cancer, with translational relevance to diagnosis and treatment. IF: 4.7
Views are our own.
⭐️🚨Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency @NatureMedicine@OncoAlert#PrecisionMedicine
https://t.co/9qGjQzDnRQ
Exciting data supporting combination of ONC201 (small molecule - imipridone class) and TRAIL for endometrial cancer https://t.co/iYBySxL9zy #cancer#cancerResearch#Immunotherapy
⭐️🔺Just in 👉🏼 LAG3 emerges as #Immunotherapy after PD1/PDL1 & CTLA4 👉🏼Relatlimab + Nivolumab versus Nivolumab in Untreated Advanced Melanoma ! @nejm @HTawbi_MD @MDAndersonNews https://t.co/yXo9UOlfcV
ACS is proud to lead the national fight against #cancer. Millions of lives have been saved through funding research. In 2022, let's accelerate that effort! Learn more and join us in the fight at https://t.co/NrZRdJqS3E. @AmericanCancer#oneACSagainstcancer
@Scott_Waldman moving the needle forward on GUYC2C re-activation for colon cancer prevention https://t.co/x6RQ78ZttP For an excellent review @adamsnookphd on GUYC2C as a therapeutic target for GI cancers see https://t.co/ml1ohYsXRt #Gastroenterology#CANCER
Intensively happy to share our newest study uncovering #mitochondrial adaptation as mechanism of response and #resistance to #BCL2 inhibitor combination in #AML#leukemia@NatureCancer.
Congratulations to our amazing PhD student Claudie Bosc and all co-authors.